Fabian Acker

5PUBLICATIONS
21CO-AUTHORS
Haematological tumoursPredictive and prognostic markersGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 10, 2026
Treatment intensification does not improve outcomes beyond rituximab-based therapy in primary mediastinal B-cell lymphoma: a multicenter retrospective analysis.

|Mar 24, 2026
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315).

Fabian Acker, Katharina Wenger, Martin Reck

|Jul 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.

Fabian Acker, Jörg Chromik, Emily Tiedjen

|Jul 01, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.

Nora Liebers, Johannes Duell, Donnacha Fitzgerald

Pageof 1

Frequent Collaborators

3 joint publications

Martin Sebastian

1 joint publications

Donnacha Fitzgerald

1 joint publications

Eva Kaebisch

1 joint publications

Stephan Fuhrmann